Literature DB >> 7584953

Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease.

H Takayama1, J Ray, H K Raymon, A Baird, J Hogg, L J Fisher, F H Gage.   

Abstract

The clinical use of fetal neural grafts as an intracerebral source of dopamine for patients with Parkinson's disease has met with limited success. Since basic fibroblast growth factor (bFGF) enhances the survival and growth of dopaminergic neurons in vitro, we explored whether cells genetically modified to produce bFGF would improve the functional efficacy of dopaminergic neurons implanted into rats with experimental Parkinson's disease. Results show that bFGF-producing cells grafted together with fetal dopamine neurons have potent growth-promoting effects on the implanted neurons in vivo. Moreover, rats implanted with such co-grafts display the most pronounced behavioural improvements post-grafting. These findings not only provide insight into the function of bFGF in situ, but also suggest an approach for enhancing the survival and function of dopamine neurons grafted into the damaged brain.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7584953     DOI: 10.1038/nm0195-53

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  17 in total

1.  Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease.

Authors:  J Garcia de Yebenes; J Yebenes; M A Mena
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 2.  New directions in the drug treatment of Parkinson's disease.

Authors:  J L Montastruc; O Rascol; J M Senard
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

3.  Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration.

Authors:  D Kirik; C Winkler; A Björklund
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

Review 4.  Ethical issues in neurografting of human embryonic cells.

Authors:  G J Boer
Journal:  Theor Med Bioeth       Date:  1999-09

5.  Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways.

Authors:  Shih-Ling Hsuan; Heather M Klintworth; Zhengui Xia
Journal:  J Neurosci       Date:  2006-04-26       Impact factor: 6.167

6.  Sonic hedgehog facilitates dopamine differentiation in the presence of a mesencephalic glial cell line.

Authors:  N Matsuura; D C Lie; M Hoshimaru; M Asahi; M Hojo; R Ishizaki; N Hashimoto; S Noji; H Ohuchi; H Yoshioka; F H Gage
Journal:  J Neurosci       Date:  2001-06-15       Impact factor: 6.167

7.  Basic fibroblast growth factor prevents the memory impairment induced by gastrin-releasing peptide receptor antagonism in area CA1 of the rat hippocampus.

Authors:  Thales Preissler; Tatiana Luft; Flávio Kapczinski; João Quevedo; Gilberto Schwartsmann; Rafael Roesler
Journal:  Neurochem Res       Date:  2007-04-04       Impact factor: 3.996

Review 8.  Neurotrophic factors for the investigation and treatment of movement disorders.

Authors:  Justo Garcia De Yébenes; Marina Sánchez; Maria Angeles Mena
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 9.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Long-lasting induction of astrocytic basic fibroblast growth factor by repeated injections of amphetamine: blockade by concurrent treatment with a glutamate antagonist.

Authors:  C Flores; D Rodaros; J Stewart
Journal:  J Neurosci       Date:  1998-11-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.